The eukaryotic subtilisin prohormone convertase 2 (PC2) is known to require in vivo exposure to the neuroendocrine protein 7B2 in order to produce an enzymatically active species capable of proteolytic action on prohormone substrates. In the present study, we examined the role of the pentabasic site within 27-kDa 7B2 in this process. We prepared two His-tagged recombinant 7B2s by overexpression in bacteria: 7B2-Ser-Ser (SS), with an inactivating mutation in the CT peptide from Lys171-Lys172 (KK) to SS, rendering the CT peptide non-inhibitory; blockade-SS, a double mutant of both the CT peptide as well as of the pentabasic furin cleavage site. These puri®ed proteins were used in a cell-free proPC2 activation assay. Both 7B2-SS as well as blockade-SS were able to facilitate the activation of proPC2 (as judged by ef®cient production of enzyme activity), suggesting that cleavage at the furin site is not required for 7B2s lacking inhibitory CT peptides. Plasmids encoding proPC2 and various 7B2s were transiently transfected into human embryonic kidney (HEK293) cells and PC2 enzymatic activity and CT forms in each overnight conditioned medium were measured. Cells transfected with proPC2 and wild-type 7B2 secreted CT peptide cleavage products, but cells transfected with proPC2 and the blockade mutant overwhelmingly secreted intact, 27-kDa, blockaded 7B2. Medium obtained from HEK293 cells transfected with proPC2 and either wild-type 7B2, 7B2-SS, or blockade-SS exhibited PC2 activity, but medium from cells expressing the 7B2 blockade mutant did not. We conclude that cleavage at the 7B2 furin consensus site is required to produce PC2 capable of ef®cient proteolytic inactivation of the CT peptide. Keywords: 7B2, furin, PC2, prohormone convertase, secretory pathway, trans-Golgi network. A family of enzymes known as the prohormone convertases are thought to be responsible for the conversion of polypeptide hormone and neuropeptide precursors to active peptide products, most often by cleavage at pairs of basic residues (reviewed in Zhou et al. 1999) . Prohormone convertases 1 and 2 (PC1 and PC2) have been con®rmed to be involved in the maturation of many different precursors, from proopiomelanocortin (POMC) to proinsulin (see review by Zhou et al. 1999) .
A family of enzymes known as the prohormone convertases are thought to be responsible for the conversion of polypeptide hormone and neuropeptide precursors to active peptide products, most often by cleavage at pairs of basic residues (reviewed in Zhou et al. 1999) . Prohormone convertases 1 and 2 (PC1 and PC2) have been con®rmed to be involved in the maturation of many different precursors, from proopiomelanocortin (POMC) to proinsulin (see review by Zhou et al. 1999) .
PC2 exhibits a peculiar cell biology compared with other related convertases; its propeptide is removed late within the secretory pathway, and it requires intracellular interaction with the neuroendocrine protein 7B2 for maturation to an active enzyme species (Seidel et al. 1998; reviewed in Muller and Lindberg 1999) . The interaction of PC2 with 7B2 is an interesting example of transient protein±protein interaction within the regulated secretory pathway. We have shown that 7B2 binds to fully folded proPC2 and escorts the zymogen to the Golgi, where autocatalytic activation takes place as a consequence of exposure to a low pH compartment (reviewed in . Cleavage of 7B2 to a 21-kDa domain and the carboxylterminal or CT peptide is thought to occur at a pentabasic site fairly rapidly after synthesis, but within the Golgi, by the action of a constitutively expressed convertase known as furin (Ayoubi et al. 1990; Paquet et al. 1994; Benjannet et al. 1998; Muller et al. 1997) . While earlier studies appeared to indicate that the furin pentabasic site is required for the facilitating effect of 7B2 on the maturation of proPC2 in neuroendocrine cells (Muller et al. 1997; Benjannet et al. 1998) , the ability of the 21-kDa domain ± which lacks this site ± to ef®ciently facilitate the production of active PC2 (Zhu and Lindberg 1995) implies that the furin site itself cannot be critical to this process.
Intact 27-kDa 7B2 is a potent inhibitor of PC2. Once cleaved from the 21-kDa domain, the 7B2 CT peptide remains highly inhibitory to PC2 (Zhu et al. 1996) . Termination of inhibitory activity is achieved only by internal cleavage at the KK site, most likely by PC2 itself, followed by carboxypeptidase action to remove the carboxyterminal KK pair (Zhu et al. 1996) . The exact mechanism by which the CT peptide displaces the propeptide within the newly formed catalytic site is an interesting area for study; recent data indicate that unlike the propeptides of other convertases, the PC2 propeptide possesses a relatively low (micromolar) af®nity for PC2 (Muller et al. 2000) , and hence may be easily displaced by the CT peptide, which exhibits a nanomolar af®nity for PC2. In vitro, an overwhelming molar excess of PC2 is required to observe internal cleavage of CT peptide added in trans; however, in vivo, this cleavage appears to be ef®cient since neuroendocrine cells predominantly store cleaved CT peptide (Zhu et al. 1996) .
In this study, we have attempted to shed light on the proPC2/7B2 interaction by examining the role of the pentabasic furin site. Our data support the idea that this site is not required for activation of proPC2, but suggest instead that it plays a critical role in the inactivation of the inhibitory CT peptide.
Materials and methods
The 7B2 mutations and transfection of cell lines Mutations in C-terminal region were generated in rat 7B2 cDNA by a two-step PCR-mediated methods as described previously (Vallette et al. 1989; Zhu and Lindberg 1995) . For the mutations at the C-terminal region (KK), the primers used for generating the fragment were 5
H -AATGTTGTGGCATCGTCGTCTGTCCCC CAC-3 H and 5 H -GGCGCCAAGCTTTTATTCTGGCTCCTTC-3 H . The product from the ®rst round of PCR was used as a carboxylterminal primer with the 5 H primer (5 H -GGCGCAAGCTTCACC ATGACCTCAAGGATGG-3 H ) in the second round of PCR. The PCR fragment was then cloned into pCEP4 (Invitrogen, Carlsbad, CA, USA). Rat 7B2 cDNA and the blockade mutant previously described (Zhu and Lindberg 1995) were used as templates for the preparation of 7B2-SS and blockade-SS, respectively. All cDNAs generated by PCR were veri®ed by DNA sequencing. For double transient transfections, human embryonic kidney (HEK293) cells were transfected using 2 mg of each cDNA (mouse PC2 and 7B2s) and 10 mL of LipofectAMINE in 1 mL per 35 mm well.
Preparation of recombinant His-tagged 7B2s
Recombinant His-tagged 7B2s were prepared using the QIAexpress system (Qiagen Inc., Chatsworth, CA, USA). His-tagged blockade mutant of 7B2 and mutations in C-terminal region were generated using the same 3 H primer as above, the 5 H primers containing the mutations (from KK to SS) used for the eukaryotic vectors, and the 5 H primer (5 H -CGGCCGGATCCTATAGTCCACGGACTCCT-3 H ). The PCR fragments were digested with BamHI and HindIII, and ligated into pQE30 (Qiagen). His-tagged 7B2 constructs were veri®ed by DNA sequencing. Proteins were expressed in Escherichia coli XL-1 Blue (Stratagene, La Jolla, CA, USA), induced with 1 mm of IPTG (®nal concentration) and puri®ed based on the guanidine±HCl extraction method (Martens et al. 1994) . Brie¯y, cells from a 500-mL culture were lysed in 20 mL of buffer A (10 mm HEPES, pH 7.5 containing 6 m guanidine HCl) for 1 h in the cold room, centrifuged for 15 min at 10 000 g, loaded onto the Ni-NTA column (1.5 mL of resin) previously equilibrated with buffer A and washed with buffer A using a Waters FPLC. The denatured protein was renatured using a linear gradient of buffer A and buffer B (10 mm HEPES, pH 7.5 and 0.1 m NaCl) with a¯ow rate of 0.4 mL/min over 130 min. After washing with 10 column volumes of 10 mm HEPES, pH 7.5 containing 50 mm NaCl, proteins were eluted from the column with 30 mL of buffer C (10 mm HEPES, pH 7.5 containing 250 mm imidazole, 50 mm NaCl, and 0.02% NaN 3 ) at a¯ow rate of 0.3 mL/min. Fractions were stored at 2 708C; an aliquot of each was analyzed on a 15% sodium dodecyl sulfate±polyacrylamide gel (SDS±PAGE) using Coomassie staining. A predominant band was observed on a SDS±PAGE gel with the expected molecular mass and an estimated purity of greater than 90%.
Metabolic labeling and immunoprecipitation
In order to investigate the binding of 7B2 to PC2, HEK293 cells transiently transfected with 7B2 cDNAs were metabolically labeled with 0.3 mCi/mL [ 35 S]methionine/cysteine Pro-mix (Amersham Pharmacia Biotech, Piscataway, NJ, USA) for 20 min and chased for 2 h in Dulbecco's modi®ed Eagle's medium (DMEM) containing 2% fetal bovine serum (FBS). Cells were extracted essentially as previously described (Muller et al. 1997) . Five hundred microliters of each sample were preincubated with 0.1 mL 20% Protein A-Sepharose CL-4B (Pharmacia, Uppsala, Sweden) hydrated and washed with AG buffer (0.1 m sodium phosphate, pH 7.4, 1 mm EDTA, 0.1% Triton X-100, 0.5% NP-40, and 0.9% NaCl) at 48C for 1 h, and then centrifuged. Five microliters of PC2 or 7B2 antiserum were then added to the supernatant, along with 0.5 mm p-chloromercuriphenylsulfonic acid (Sigma Chemical Co., St Louis, MO, USA) and 0.5 mm phenylmethanesulfonyl¯uoride (Boehringer Mannheim Corp., Indianapolis, IN, USA) (®nal concentrations) and samples were incubated overnight at 48C with agitation. One hundred microliters of 20% Protein A±Sepharose, hydrated and washed three times with AG buffer, were then added and the samples rocked at 48C for 1 h. The beads were washed with twice with AG buffer, once with 0.5 m NaCl in PBS, and twice with PBS. Immunoprecipitates were resuspended in Laemmli sample buffer and analyzed using 8.8% or 15% SDS±PAGE. After electrophoresis, gels were ®xed with 25% methanol containing 10% acetic acid for 30 min and exposed to a Storm phosphoimager screen (Molecular Dynamics, Sunnyvale, CA, USA) and analyzed with ImageQuant.
In vitro activation of proPC2
Golgi-enriched subcellular fractions were prepared from CHO/PC2 cells as described previously (Muller et al. 1997) . Golgi fractions (3 mg of protein) were incubated in 100 mm sodium acetate, pH 5, in the presence of 1% Triton X-100, 5 mm CaCl 2 and an inhibitor mixture composed of 1 mm pepstatin, 1 mm trans-epoxysuccinic acid, 280 mm tosylphenylalanine chloromethyl ketone, and 140 mm tosylysyl chloromethyl ketone (®nal concentrations). Incubations were conducted at 378C for the indicated periods of time. PC2 activity was estimated using 200 mm pyr-Glu-Arg-Thr-Lys-Argmethylcoumarinamide (MCA) as a substrate. The¯uorescence of the product was quanti®ed by reference to a free amino methyl coumarin (AMC) standard at 380 nm (excitation)/460 nm (emission).
PC2 enzyme assay
The PC2 enzyme assay was performed essentially as described previously with the exception of the substitution of octyl glucoside for Brij. Brie¯y, PC2 activity in conditioned medium was measured in 100 mm sodium acetate (pH 5.0), containing 5 mm CaCl 2 , 0.4% octyl glucoside, and the proteinase inhibitor cocktail indicated above, using the same substrate. When present, the human 7B2 carboxy-terminal domain (CT peptide 1±31), a PC2-speci®c inhibitor , was added at a 1 mm ®nal concentration. Incubations were conducted at 378C. The results presented represent the mean (^SD) of triplicate measurements of PC2 activity from a representative experiment.
HPLC
In order to distinguish between CT1±18 and CT1±16, we performed reverse-phase HPLC and radioimmunoassay (RIA) using the LSU17 antiserum against rat CT1±16 peptide (Zhu et al. 1996b) . Overnight conditioned medium obtained from HEK293 cells transfected with PC2 and either wild-type 7B2 or the blockade mutant was incubated at pH 5, 378C and harvested at different time points: 0, 2.5, and 6 or 8 h. Each aliquot was diluted 4±5 times with 0.06% tri¯uoroacetic acid (TFA) and fractionated on a C4 reverse-phase column (Vydac, Hesperia, CA, USA) using a gradient of 0±100% B over 100 min, with B being 80% acetonitrile containing 0.052% TFA. The¯ow rate was 1 mL/min. Two hundred microliter duplicate aliquots of each fraction were dried in the presence of carrier bovine serum albumin (BSA) and analyzed for CT peptide immunoreactivity by RIA using the LSU17 antiserum; in order to expose the epitope and provide identi®cation of basic-residue extended peptides, separate aliquots of fractions were incubated either in the presence or in the absence of TPCKtreated carboxypeptidase-B (CPB; Calbiochem). For this purpose, dried HPLC fractions were resuspended with 80 mL of 100 mm Tris-HCl, pH 8.0 containing 0.01% BSA and 0.1% sodium azide, and 20 mL of 1600-fold diluted stock CPB was added, followed by incubation for 20 min at 378C. Reactions were terminated by boiling for 5 min, the tubes cooled, and antiserum and radioactive peptide added. The RIA was then incubated at 48C overnight prior to separation of bound labeled peptide from free as previously described.
Carboxypeptidase E (CPE) treatment
In order to investigate whether the recovery of PC2 activity could be improved in the presence of CPE, the overnight conditioned medium obtained from HEK293 cells transfected with proPC2 and either wild-type 7B2 or the CT mutants, was measured for PC2 activity by incubating at pH 5 for varying lengths of time in the presence and absence of 0.1 mg of puri®ed recombinant carboxypeptidase E (a kind gift of Lloyd Fricker, Albert Einstein College of Medicine) under the normal PC2 assay conditions (50 mL reaction volume). For con®rmation of the enzymatic activity as PC2, reactions were performed in the presence and absence of 1 mm CT 1±31 peptide.
Results

Schematic representation of CT mutants versus wild-type 7B2
The 7B2 mutants prepared for this study are shown in Fig. 1 . 7B2 mutants bearing a blockade of the pentabasic furinsensitive cleavage site are termed`blockade' mutants, while lysine to serine mutations of the CT peptide ± rendering it both non-inhibitory and non-cleavable ± are termed`SS' mutants.`Blockade-SS' thus refers to a 7B2 lacking both the furin consensus site and the pair of lysines which confer inhibitory potency.
Non-inhibitory 7B2 mutants can facilitate proPC2 activation in Golgi-enriched membranes We ®rst tested the ability of recombinant 7B2s to interact with proPC2 in a Golgi-enriched membrane assay (Muller et al. 1997) ; in this assay, proPC2 present in Golgi-enriched subcellular fractions prepared from CHO/proPC2 cells is not able to form active PC2 unless biologically active 7B2 is included in the incubation mixture. When Golgi membranes were incubated with the same amounts of recombinant puri®ed 7B2-SS or blockade-SS under conditions favorable for PC2 activity (pH 5, 5 mm CaCl 2 , and proteinase inhibitors), PC2 exhibited abundant activity (Fig. 2) . (We Fig. 1 Schematic representation of 27-kDa 7B2 (wild-type) and mutants used in this study.`CT' corresponds to the CT peptide, the carboxy-terminal domain of 7B2 that potently and speci®cally inhibits PC2 activity.`Wild-type' represents the naturally occurring 27-kDa 7B2. 7B2-SS represents wild-type 27-kDa 7B2 containing a mutation from KK to SS in the CT peptide; it has previously been shown that these residues are responsible for inhibition of PC2.`Blockade mutant' represents the 7B2 protein containing a blockade mutation from R 151 RKRR 155 to SQNSN at the pentabasic furin cleavage site.
Blockade-SS' is a non-inhibitory double mutant of both the furin cleavage site as well as of the CT peptide.
were unable to use either wild-type 27-kDa 7B2 or the simple blockade mutant to observe facilitation of activation of proPC2 in this in vitro system, because the PC2 generated was completely inhibited by these highly inhibitory proteins.) These data led us to conclude that the furin cleavage site in 7B2 is not likely to be important for facilitating proPC2 activation, at least in 7B2s lacking inhibitory CT peptides. To con®rm this conclusion, 7B2 mutants were tested in an in vivo system for their activities against proPC2.
7B2-SS and blockade-SS mutants are also active in the facilitation of maturation of proPC2 in an in vivo system In order to observe the biological activity of CT peptide mutants in the facilitation of proPC2 activation in an in vivo system, we transiently transfected plasmids encoding either wild-type 27-kDa 7B2, 7B2-SS, blockade mutant or blockade-SS into HEK293 cells. After transfection, PC2 activity in the overnight conditioned medium was measured. The data presented in Fig. 3(a) show rapid activation of secreted proPC2 after cellular transfection with 7B2-SS and blockade-SS, and slower, but ultimately equivalent activation with wild-type 7B2 (since media obtained from 27-kDa 7B2, 7B2-SS, and blockade-SS expressing cells exhibited the same maximal PC2 activity after 16 h of incubation at acidic pH (not shown). There was no or very low activation with the blockade mutant during the 7 h incubation period. These results are consistent with our in vitro studies using recombinant proteins, with the exception of wild-type 27-kDa 7B2 (secreted as the 21-kDa form lacking the inhibitory CT peptide, indicating intracellular cleavage at the furin site). The slow activation of proPC2 seen with wild-type 7B2 is consistent with the scenario of initial inhibition by the CT peptide and a subsequent slow cleavage event. Figure 3 (b) shows that the furin cleavage sites in blockade-SS and the blockade mutant were indeed blocked. Therefore, the presence of PC2 activity in medium obtained from HEK293 cells transfected with proPC2 and blockade-SS was not due to ineffectiveness of the blockade of the furin cleavage site. The presence of mature PC2 in all coimmunoprecipitates in Fig. 3(b) indicates that propeptide removal is not affected by the blockade mutations.
Taken together, these data indicate that given the presence of a non-inhibitory CT peptide, cleavage at the 7B2 pentabasic site is not required for proPC2 activation. Since SS-containing proteins exhibited no inhibition of PC2 under any conditions, these data also con®rm that the KK site in the CT peptide is absolutely required for inhibition (van Horssen et al. 1995; Apletalina et al. 2000a) . Fig. 2 The non-inhibitory proteins 7B2-SS and blockade-SS are able to activate PC2 in an in vitro system using Golgi-enriched membranes. Golgi-enriched membranes from CHO/proPC2 cells were preincubated with recombinant wild-type 7B2, 7B2-SS, blockade mutant, and blockade-SS in 100 mM HEPES, pH 7.4 buffer containing 0.5% Triton X-100 for 1 h at 378C. PC2 activity was then estimated at 5 h of incubation under the usual PC2 assay conditions. The 7B2 blockade mutant does not undergo internal cleavage at the KK site Since the medium containing PC2 and wild-type 7B2 exhibited PC2 activity but medium from similar transfections using 7B2 bearing a blockade mutation did not, we speculated that furin-mediated cleavage may be important only in the presence of 7B2s containing an inhibitory CT peptide (i.e. not SS mutants). We therefore decided to examine the pro®le of immunoreactive CT peptide fragments present in the conditioned media obtained from HEK293 cells transfected with proPC2/27-kDa 7B2 and proPC2/blockade. The overnight conditioned medium obtained from HEK293 cells transfected with either PC2/ 27-kDa 7B2 or PC2/blockade was incubated for 0, 6 h or 8 h at pH 5 and 378C in order to provide conditions optimal for PC2 activity; HPLC was then performed to separate CT 1±16 (lacking carboxy terminal basics) and CT 1±18 (bearing carboxy terminal basics). The CT 1±16 RIA, performed with or without CPB treatment for removing carboxy-terminal basic amino acids, was used to assess the molecular species present in each fraction. As shown in Fig. 4(a) , the overnight conditioned medium obtained from HEK293 cells transfected with proPC2/wild-type 7B2 contained both CT 1±18 and CT 1±16 in the starting material (i.e. not incubated at pH 5). The amount of CT 1±18 was greatly increased after 8 h of incubation (Fig. 4b) , con®rming that the PC2 generated by wild-type 7B2 can cleave the CT peptide at the KK site (Zhu et al. 1996b) . The amount of CT 1±16 in the reaction was not signi®cantly increased during incubation of wild-type 7B2 (note different scales on Figs 4a and b) .
There was no CT 1±16 immunoreactive material in HPLC fractions obtained from the starting material from PC2/blockade mutant transfections; incubation of all fractions with CPB also failed to generate any immunoreactivity, indicating a lack of CT1±18 (results not shown). However, after incubation of this same starting material at pH 5 for 6 h, HPLC separation and treatment of fractions with CPB, CT 1±16-ir was evident; this was mostly present as a late-eluting peptide (Fig. 4c) . This immunoreactive peak was only observed following incubation of fractions with CPB, indicating the presence of carboxy-terminal basic residues. This peak may represent the 23-kDa, aberrantly cleaved form terminating in the inhibitory lysine pair within the CT peptide, KK. Since this aberrantly cleaved peptide was not detected in HPLC fractions obtained from the starting material, it must have been generated during the long incubation at pH 5 rather than intracellularly. However, the biosynthetic experiments in Fig. 3(b) show the presence of very small amounts of high molecular weight blockade mutant derivatives . It is likely that the small amounts of the 23-kDa protein present in the HPLC starting material were not detected by CT 1±16 RIA because much less material was used for HPLC than for the immunoprecipitation shown in Fig. 3(b) .
We conclude from these experiments that intracellular internal cleavage of the CT peptide is severely hampered in 7B2s lacking a furin consensus sequence. The methods used are identical to those in panels (a) and (b), except that medium was harvested at 6 h. The novel form of immunoreactive CT peptide ± possibly representing a 23-kDa form generated by internal cleavage at KK ± is indicated with an arrow. Latent PC2 activity secreted by blockade mutant-transfected cells is rescued by adding exogenous CPE In order to examine whether the PC2/blockade mutant 7B2 complex can function enzymatically, we added recombinant CPE to relieve the putative inhibition caused by the presence of terminal lysines on the aberrant CT form. Overnight conditioned medium obtained from HEK293 cells transfected with proPC2 and the blockade mutant was assessed for PC2 activity at pH 5.0 in the presence and absence of added recombinant CPE. As shown in Fig. 5 , in the absence of CPE there was no activity in the medium obtained from blockade mutant-expressing cells; this cannot be accounted for by differing expression levels of the two 7B2s (Fig. 3b) . Interestingly, PC2 activity in medium obtained from blockade mutant-expressing cells was effectively rescued by coincubation with added recombinant CPE protein. In the presence of CPE, the activity of incubations containing wild-type 7B2 approximately doubled; however, the activity of the blockade mutant increased by 19-fold (Fig. 5) . The rescued PC2 activity was completely inhibited by 1 mm CT1±31 peptide, con®rming the measured enzymatic activity as PC2. CPE alone had no effect on PC2 activity in this assay (data not shown). These results support the notion that the association of the blockade mutant with PC2 results in the formation of a PC2 molecule that can be activated and thus is not equivalent to PC2 which arises from proPC2 in the absence of 7B2 exposure.
Discussion
The interaction of 7B2 and proPC2, a reaction required to generate active PC2, is an interesting example of a non-classical chaperone event occurring within the secretory pathway. ProPC2 which does not have the opportunity to interact with 7B2 intracellularly is cleaved to a catalytically inert mature PC2 molecule. We have speculated that the interaction of proPC2 with 7B2 generates a conformational change within proPC2 which permits subsequent activation; alternatively, interaction of proPC2 with 7B2 may prevent the spontaneous assumption of an inactive conformation. In this paper, we have attempted to address the role of the furin cleavage site in this unusual facilitation reaction.
In order to gain further information on the role of the furin site in 7B2-assisted maturation of proPC2 to PC2 we used 7B2 mutants both in in vivo and in in vitro systems. The 7B2s used fell into two classes: inhibitory 7B2s contained the KK pair in the 7B2 CT peptide required for effective inhibition of PC2 van Horssen et al. 1995) , while in non-inhibitory 7B2s, these lysines were replaced with serines. Furin site blockade mutants were combined with both types of CT peptides. The noninhibitory 7B2 proteins 7B2-SS and blockade-SS were able to facilitate proPC2 maturation to an active enzyme species both in an in vitro Golgi membrane-enriched system as well as in vivo, as judged by the ef®cient production of enzyme activity in transiently transfected HEK293 cells. While the blockade mutation may indeed weaken binding of wild-type 7B2 to proPC2 in the ER , it is clear that the pentabasic site is not de®nitive for binding of 7B2 to proPC2, a view supported by the ef®cacy of the 21-kDa protein in promoting proPC2 maturation. These data demonstrate that for non-inhibitory 7B2s, the furin cleavage site is not required for maturation of proPC2 into an active enzyme.
However, a very different picture emerged when we examined the role of the furin site in inhibitory 7B2s, i.e. 7B2s containing the KK pair in the CT peptide, such as the 7B2 blockade mutant and wild-type 7B2. Interestingly, the 7B2 blockade mutant exhibited either no, or very low, PC2 activity when the medium obtained from transiently transfected cells was assayed. These data indicate a potentially new role for the furin site in the inactivation of the CT peptide.
We propose the following model for the interaction of proPC2 with the various domains of 7B2 in constitutive cells (depicted in Fig. 6 ). Twenty-seven kilodalton wild-type 7B2 ®rst interacts with fully folded proPC2 (Muller et al. 1997) , most likely in the endoplasmic reticulum, through at least two binding sites: one in the 21-kDa domain, and the other via the CT peptide. Since the active site of PC2 is occupied by propeptide at this time, neither site can correspond to binding to the active site. While an independent binding site for the CT peptide on proPC2 has never been formally demonstrated, in preliminary experiments we have found that CT peptide antiserum can immunoprecipitate proPC2 from the medium of 7B2-expressing cells (L. Muller, Fig. 5 PC2 enzymatic activity in medium from HEK293 cells transfected with the blockade mutant is rescued by the addition of carboxypeptidase E (CPE). Assays of PC2 enzymatic activity in the overnight medium from each transfected cell type were performed in the presence and absence of added CPE as described in`Materials and methods'. PC2 activity is represented by: O, wild-type 7B2 without CPE; K, wild-type 7B2 with CPE; X, blockade mutant without CPE); and W, blockade mutant with CPE. The variability of duplicates ranged between 1% and 13%, with an average of 8%.
unpublished results). In addition, our recent mutagenesis work has shown that PC2 contains a sequence ± not located in the active site ± which is responsible for binding of the CT peptide, as mutagenesis of this sequence results in nearcomplete lack of ability to be inhibited by the CT peptide by an otherwise active enzyme (Apletalina et al. 2000b) . Taken together with the work reported here, these observations support the notion of an independent, non-active site, CT peptide binding domain within PC2.
When the proPC2/7B2 complex arrives in the trans-Golgi network (TGN), resident furin immediately cleaves the pentabasic amino acid site within 7B2, resulting in conformational freedom of the complex (Fig. 6) . Blockade mutants undergo no such cleavage, and the CT peptide remains attached to the 21-kDa domain; this complex may be conformationally restricted. 21-kDa 7B2 generated from wild-type 7B2 then interacts with proPC2 to effect a conformational change which renders proPC2 competent for autoactivation. This conformational change may not occur as robustly or as rapidly if the 7B2 molecule remains bound to proPC2 at two sites rather than at one site (as is the case for the inhibitory ± but not the non-inhibitory ± blockade mutant).
We speculate that proPC2s bound to wild-type 7B2, or non-inhibitory 7B2s bound only at one end, can undergo autocatalytic, intramolecular activation (shown in Fig. 6 ). PC2 then immediately binds the KK pair within the CT peptide at its active site. The non-inhibitory 7B2 blockade protein is not bound at the active site, and therefore its PC2 is fully active at this point. The proPC2 bound to the inhibitory blockade mutant remains in a constrained conformation. While proPC2 bound to the inhibitory blockade mutant cannot ef®ciently undergo productive maturation (as de®ned by the generation of an active enzyme species), under certain conditions it can undergo such maturation eventually, as evidenced by its ability to acquire activity under acidic conditions in the presence of excess carboxypeptidase (this paper) and to exhibit activity in the conditioned medium of neuroendocrine cells (Zhu and Lindberg 1995) .
Wild-type 7B2 must still undergo inactivation of the CT peptide via internal hydrolysis at the KK pair, followed by carboxypeptidase action to remove terminal basic residues (Zhu et al. 1996b ; shown in Fig. 6 ). The inability of the blockade mutant to ef®ciently undergo this CT peptide inactivation reaction suggests that the proPC2 conformational change normally effected by 7B2 may be much slower than normal, and may result in an aberrant 7B2/PC2 complex which carboxypeptidases can only poorly access. However, the blockade mutant/proPC2 complex is not intrinsically crippled since, as discussed above, it can, under certain circumstances, still yield active enzyme.
Wild-type 7B2 which has undergone internal CT peptide cleavage and carboxypeptidase action is no longer inhibitory, and the resulting associated PC2 molecule is fully active. The inhibitory blockade mutant, on the other hand, remains intact and inde®nitely bound to PC2, unless the pH is lowered to the acidic range normally seen only in neuroendocrine cells, or generated by experimental manipulation. In neuroendocrine cells (or in acidic medium), when this complex is activated to PC2 by autocatalytic action, slow cleavage to an aberrant 7B2 form terminating in the inhibitory lysines occurs, and overexposure to carboxypeptidase is required to overcome this type of inhibition (these latter processes are not shown in Fig. 6 , which depicts the molecules secreted from constitutive cells).
While the molecular determinants involved in the binding of proPC2±7B2 are not completely understood, several elements have been described thus far for each protein partner. For 7B2, these include the 36-residue polyprolinecontaining central peptide (Zhu et al. 1996a; van Horssen and Martens 1998; ; and as discussed above, an unde®ned region within the CT peptide. For proPC2, the elements involved in binding 7B2 are likely to include an aromatic acid-rich loop within proPC2 (Zhu et al. 1998; Benjannet et al. 1998 ) and the PC2-speci®c sequence known to bind the CT peptide (Apletalina et al. 2000b) . It is tempting to speculate that the 36-residue polyproline-rich region within 7B2 binds the aromatic acidrich region within PC2 (residues 186±206, containing the critical Y194), while the CT peptide binds the PC2-speci®c sequence within proPC2, residues 242±248 (QP[Y/ F]MTD[L/I]), thus forming the bridge hypothetically illustrated in Fig. 6 . Obtaining a crystal structure of the proPC2/7B2 complex would aid us greatly in understanding the molecular positioning of these various biologically important elements.
